European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Sunlenca, lenacapavir, Date of authorisation: 17/08/2022, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 14 July 2025 - 17:33

Human medicines European public assessment report (EPAR): Sunlenca, lenacapavir, Date of authorisation: 17/08/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 14 July 2025 - 17:16

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Evrysdi, risdiplam, Date of authorisation: 26/03/2021, Revision: 11, Status: Authorised

Submitted by Anonymous (not verified) on 14 July 2025 - 17:13

Human medicines European public assessment report (EPAR): Evrysdi, risdiplam, Date of authorisation: 26/03/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Vabysmo, faricimab, Date of authorisation: 15/09/2022, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 14 July 2025 - 17:08

Human medicines European public assessment report (EPAR): Vabysmo, faricimab, Date of authorisation: 15/09/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Pomalidomide Krka, pomalidomide, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 14 July 2025 - 16:42

Human medicines European public assessment report (EPAR): Pomalidomide Krka, pomalidomide, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised

EMA Information Day on submission predictability of initial marketing authorisation December 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 3 December 2025, 13:30 (CET) to 3 December 2025, 17:30 (CET)

Submitted by Anonymous (not verified) on 14 July 2025 - 16:19

EMA Information Day on submission predictability of initial marketing authorisation December 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 3 December 2025, 13:30 (CET) to 3 December 2025, 17:30 (CET)

Human medicines European public assessment report (EPAR): Plavix, clopidogrel, Date of authorisation: 15/07/1998, Revision: 53, Status: Authorised

Submitted by Anonymous (not verified) on 14 July 2025 - 16:06

Human medicines European public assessment report (EPAR): Plavix, clopidogrel, Date of authorisation: 15/07/1998, Revision: 53, Status: Authorised

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 14 July 2025 - 15:57

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 13, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More